Pfizer (PFE) Stock Looks Stretched Even With New Pipeline Deals
Simplywall·
- Pfizer is trading around US$ 27.40 after a 33.5 % share price decline over the past 5 years.
- The company trades at a P / E ratio of 38.7 x, exceeding the pharmaceuticals sector average of 15.2 x while remaining below peer levels.
- Analyst views are divided, with consensus pointing to potential undervaluation based on US$ 9.7 b in net savings through 2029, while bearish views suggest limited room for error.
